Inventor · disambiguated record
Stuart A. Sievers
Also filed as: SIEVERS STUART A · SIEVERS STUART AARON · SIEVERS Stuart
16 granted patents·12 pending applications·42 citations·filing 2010–2025
91Inventor score
Top patents by PatentIndex Score
28 records- 0195US10626187B2Antigen binding molecules specific for an anti-CD19 scFvKITE PHARMA INC·Filed 2017·Granted Apr 21, 2020·8 cites·12 claims
- 0293US10844120B2Humanized antigen-binding domains and methods of useKITE PHARMA INC·Filed 2018·Granted Nov 24, 2020·8 cites·15 claims
- 0392US10844371B2Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2018·Granted Nov 24, 2020·6 cites·9 claims
- 0490US11572388B2Chimeric polypeptides and uses thereofKITE PHARMA INC·Filed 2020·Granted Feb 7, 2023·2 cites·7 claims
- 0590US11384155B2Antigen binding molecules specific for an anti-CD19 scFvKITE PHARMA INC·Filed 2020·Granted Jul 12, 2022·2 cites·12 claims
- 0688US2025243295A1Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2024·Application pending·0 cites
- 0785US11834654B2Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2020·Granted Dec 5, 2023·1 cites·5 claims
- 0884US10501775B2Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2017·Granted Dec 10, 2019·6 cites·20 claims
- 0983US11608517B2Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2019·Granted Mar 21, 2023·2 cites·15 claims
- 1081US12404305B2Chimeric polypeptides and uses thereofKITE PHARMA INC·Filed 2022·Granted Sep 2, 2025·0 cites·4 claims
- 1181US12202909B2Antigen binding molecules specific for an anti-CD19 scFVKITE PHARMA INC·Filed 2022·Granted Jan 21, 2025·0 cites·9 claims
- 1280US11390655B2Modified chimeric antigen receptors and methods of useKITE PHARMA INC·Filed 2018·Granted Jul 19, 2022·1 cites·6 claims
- 1378US8754034B2Structure-based design of peptide inhibitors of amyloid fibrillationEISENBERG DAVID S·Filed 2010·Granted Jun 17, 2014·5 cites·14 claims
- 1477US2024150750A1Antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 1575US11793834B2Chimeric antigen and T cell receptors and methods of useKITE PHARMA INC·Filed 2019·Granted Oct 24, 2023·1 cites·17 claims
- 1674US2024115611A1Chimeric antigen and t cell receptors and methods of useKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 1773US12459979B2Modified chimeric antigen receptors and methods of useKITE PHARMA INC·Filed 2022·Granted Nov 4, 2025·0 cites·6 claims
- 1866US2024343820A1Antigen binding molecules and methods of useKITE PHARMA INC·Filed 2024·Application pending·0 cites
- 1964US12459990B2Anti-HIV vaccine antibodies with reduced polyreactivityCALIFORNIA INST OF TECHN·Filed 2020·Granted Nov 4, 2025·0 cites·13 claims
- 2063US2025332281A2Humanized anti-cd8 antibodies and uses thereofCAPSTAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2160US2019092818A1Chimeric polypeptides and uses thereofKITE PHARMA INC·Filed 2018·Application pending·0 cites
- 2260US2021061910A1Humanized Antigen-Binding Domains and Methods of UseKITE PHARMA INC·Filed 2020·Application pending·0 cites
- 2358US2025144234A1RNA for In vivo Transfection with Increased ExpressionCAPSTAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2453US2022396628A1Anti-idiotypic antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2020·Application pending·0 cites
- 2551US2020377609A1Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding moleculeKITE PHARMA INC·Filed 2019·Application pending·0 cites
- 2646US2018280437A1Chimeric antigen receptors for melanoma and uses thereofKITE PHARMA INC·Filed 2018·Application pending·0 cites
- 2743US11820823B2T cell receptor antigen binding molecules and methods of use thereofKITE PHARMA INC·Filed 2018·Granted Nov 21, 2023·0 cites·18 claims
- 2840US2025302763A1Immune engineering amplificationCAPSTAN THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stuart A. Sievers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →